Search

Copyright of Namık Kemal Tıp Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introduction: This study aimed to evaluate the results obtained with the preference of eltrombopag according to the line of treatment in patients diagnosed with ITP. Methods: This retrospective study included 51 patients who were treated with eltrombopag for chronic ITP at 3 different centers. Diagnosis of ITP was based on the current literature. Results: Thirty patients (58.8%) received eltrombopag as second-line treatment, 16 patients (31.4%) as third-line, 3 patients (5.9%) as fourth-line treatment, and 2 patients (3.9%) as fifth-line treatment. Twenty-four out of 30 patients (80%) who received eltrombopag as second-line therapy and 12 out of 16 patients who received eltrombopag as third-line therapy demonstrated durable response with no further treatment requirements. Eltrombopag treatment in the second or third line did not affect treatment outcomes (p=0.72). Conclusion: Eltrombopag in the second or third line of treatment did not have a significant effect on treatment response. The earlier line choice of eltrombopag, duration, and possibility of sustained response should be taken into consideration. The lack of a significant relationship between the line of treatment and response to eltrombopag as a TPO-RA should be considered encouraging in terms of long-term follow-up. [ABSTRACT FROM AUTHOR]

Objective: We aimed to investigate whether the severity of fatigue and the incidences of depression and anxiety of patients with beta thalassemia minor (BTm) are different from healthy individuals using the Fatigue Severity Scale (FSS) and Hospital Anxiety and Depression Scale (HADS).Subjects and Methods: BTm patients who were followed at the University of Health Sciences Istanbul Training and Research Hospital Hematology Clinic between 2016 and 2017 and who had normal biochemical parameters, thyroid function tests and C-reactive protein levels, and did not use any medications, consume alcohol or tobacco, have any chronic diseases or sleep disturbances were included in the study. Healthy control subjects who were matched with age, sex, marital status, educational status, and body mass index (BMI) were also included for comparison.Results: Thirty-nine BTm patients and 25 healthy controls were included in the study. The BTm and the control groups were comparable in terms of gender, age, BMI, educational status and marital status (p = 0.368, 0.755, 0.851, 0.785, and 0.709, respectively). FSS score was ≥4 in 23 (59.0%) BTm subjects and in 15 (60%) control subjects (p = 1.0). HADS anxiety score was ≥10 in 20 (51.3%) BTm subjects and in 5 (20.0%) control subjects (p = 0.018), and HADS depression score was ≥7 in 20 (51.3%) BTm subjects and in 6 (24.0%) healthy control subjects (p = 0.039).There was no correlation of hemoglobin with FSS score (p = 0.526, r = -0.105), HADS anxiety score (p = 0.703, r = -0.063), or HADS depression score (p = 0.718, r = -0.06) in the BTm group.Conclusion: We found that both depression and anxiety were higher in BTm patients than in healthy individuals, but this difference was not feasible for fatigue. [ABSTRACT FROM AUTHOR]

We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rate was 44.6% (33/74) for patients ≥65 y (p >.05). The probability of overall survival (OS) was 90 vs. 51% in patients <65 y and ≥65 y (p =.016). In univariate analysis, the age affected OS (p =.04, HR: 0.212, CI: 0.047–0.946). In subgroup analysis, in treated patients, the probability of OS was 73 vs. 49% in patients <65 y and ≥65 y (p =.389). The survival difference between the young and old patients is too high to be ignored and age seems to affect the outcome of CLL patients. [ABSTRACT FROM AUTHOR]

Introduction: We aimed to investigate the association between neutrophil lymphocyte ratio (NLR) and response, and loss of response to corticosteroid treatment in immune thrombocytopenia patients (ITP). Methods: We retrospectively analyzed the data of 47 ITP patients treated with corticosteroid therapy at XXX between 2007 and 2016. NLR was calculated using complete blood count of patients at the time of diagnosis. The cut-off score for NLR was determined 2.5 according to median NLR level. Results: Twenty-three (48.9%) patients had NLR< 2.5 and 24 (51.1%) patients had NLR> 2.5. There was no statistical significant difference between NLR and treatment response, response duration and loss of response (p=0.74, p= 0.869, p=0.315). Conclusion: NLR was found to be associated with the prognosis and activity of various diseases in several studies; we could not verify such an association between NLR and response to corticosteroid therapy in ITP patients. [ABSTRACT FROM AUTHOR]